VECT-HORUS S.A.S.

It’s been a busy 2024 for of all of us at Vect-Horus, and we thank our employees for being a wonderful asset to our company.  We wish you all a peaceful and joyous holiday season.    It has also been an absolute pleasure working with our academic and industrial partners in 2024. Their commitment to our collaboration and strong professional relationships have made a lasting impact. Wishing all our partners a happy holiday season and the best of success in the year ahead.     #christmas #noel #holiday 

We’re looking forward to attending the 4th Annual mRNA-Based Therapeutics Summit Europe.     Pavlo Shpak-Kraievskyi will be in Frankfurt for the event, taking place January 28-30, 2025. Please get in touch if you would like to schedule a meeting.     #biotech #breakingbarriers #vectors #technology #mrna  

It’s been a busy and productive year at Vect-Horus.    Building on the signature of two major licensing agreements with @Novo Nordisk and @Ionis Pharmaceuticals by the end of the year 2023, Vect-Horus has signed several research collaborations in 2024 with pharma/biotech partners. These collaborations will allow us to demonstrate the diverse capabilities of our VECTRans® technology platform, which enables us to efficiently transport a diverse range of therapeutic cargoes into the brain and other tissues.    We were proud to publish an article in the scientific journal Pharmaceutics, outlining how vectors can improve delivery of therapeutics to organs and tumors.     During 2024, we have also presented at and attended numerous high-profile conferences, where we have had productive discussions with the scientific and investment communities. In particular, we presented a poster at the ARVO 2024 Annual Meeting outlining how our vectors have the potential to improve delivery of medication to the eye, in a strong demonstration of the technology’s potential.    This progress made reflects well our position as a major player in the landscape of brain delivery, and we are ready and set to tackle 2025 – starting with the Biotech Showcase conference in San Franciso in January.    Stay tuned for more updates…    #biotech #vectors #breakingbarriers #future #businessdevelopment  

Emmanuelle Bettendorf will be in San Francisco for JP Morgan week in January to attend the Biotech Showcase investor conference.   The event will take place January 13-15, 2025. Drop us a line if you would like to schedule a meeting with Vect-Horus.   #biotech #vectors #investing #biotechshowcase #JPM2025 #jpmorgan

Today we are highlighting our Chief Business Officer Jamal Temsamani, PhD.       We’ve been working with Jamal, who has over 30 years’ experience in management of R&D and development of partnerships with Pharma and Biotech companies, notably in the field of CNS drug delivery. He played an important role in concluding our partnerships with Novo Nordisk, Ionis Pharmaceuticals, Inc. and Radiomedix, Inc.       Jamal has been responsible for leading and providing strategic guidance for business development and alliance management activities, and previously worked at Idera Pharmaceuticals, Synt:em and CLL Pharma. He holds a PhD in Molecular Biology from the University of Montpellier and post-doc at the Worcester Foundation for Experimental Biology (MA, USA).      A dynamic leader with deep expertise in business development, Jamal has a big part to play at Vect-Horus and in #breakingbarriers in drug development.       #Biotech #BusinessLeadership  #Innovation #BusinessDevelopment     

Vect-Horus is enhancing the transport of therapeutic and imaging agents using a versatile and flexible targeting technology.    That’s based on our VECTrans® technology, which involves the specific design and optimization of molecular vectors that, once joined to a payload, enable its targeted delivery to specific organ such as the brain.    It means we don’t have to rely on invasive administration routes. The technology has been shown to be an effective and a safe way to transport medicines across the body’s cellular barriers, which otherwise can limit their efficacy.     Find out more about our technology https://lnkd.in/dwQK3xCT    #breakingbarriers #vectors #biotech #technology #science

We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!     Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.     “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of therapeutic and imaging agents to enhance their efficacy,” says Alexandre Tokay, co-founder and CEO of Vect-Horus    Click here for the full press release 👉 https://lnkd.in/dz_vRb8D   #leadership #biotech #strategy #technology #science 

Thanks to Juliette Badina✏️ for the very in-depth article on Vect-Horus, and its advances in the design vectors to facilitate the delivery of therapeutic molecules to target organs, in particular the central nervous system, in Pharmaceutiques.   The article, based on an interview with Jamal Temsamani and Michel Khrestchatisky, reviews the use of vectors to address neurological diseases.   It also reviews the strength of the company’s major licence agreements with Novo Nordisk and Ionis Pharmaceuticals, Inc. Pharmaceuticals.

Meet Jean-Manuel Péan, PharmD, PhD our Chief Scientific Officer and a distinguished leader in Pharmaceutical Sciences and drug development.   Jean-Manuel has spent more than 20 years in the pharmaceutical industry, mainly at Servier where he was Head of Drug Delivery Research & Formulation and then CMC Scientific Director for drug life cycle management.  He has extensive experience in all aspects of pharmaceutical development from preclinical formulation to industrial transfer, having been involved in clinical testing of more than 50 investigational products and products registered. Jean-Manuel has collaborated with numerous major drug delivery companies and Universities. He is co-inventor of several patents and has co-authored publications in peer-reviewed journals addressing advanced technologies like ligand-decorated nanoparticles. Dr Péan received his PhD in Pharmaceutical Sciences from Paris University. It’s a pleasure to continue our collaboration, Jean-Manuel! #PharmaceuticalScience #DrugDevelopment #Innovation #Leadership #Science  

Vect-Horus will be at #BIOEurope!     Faustine Ramel and Emmanuelle Bettendorf will be attending the event to be held on November 4-6 in Stockholm, Sweden.    Please get in touch if you would like to meet and catch up on the newest advancements at Vect-Horus.    https://lnkd.in/dnuNZ2D    #investing #vectors #biotech #technology #science